Navi
Right
 
Skip Navigation LinksHome Research report list Pharma & Healthcare Healthcare Global Blood Plasma Market Report: 2014 Edition
 
Social
Global Blood Plasma Market Report: 2014 Edition
Format : Pdf (Instant Download)
Date: 07, July 2014 | Pages: 84
Social
 
Electronic Access - Single User License
Tool
USD 800
Electronic Access - Corporate User License
Tool
USD 1100
Hard Copy - Mail Delivery
Tool
USD 875
 
   
 

Plasma is a composite mixture of more than 700 proteins and other substances which are vital for the smooth functioning of the human body. Plasma is the liquid component of blood, constituting around 50% of the total blood volume. Plasma in itself is approximately 90% water, with the remaining 10% comprising of proteins, minerals, clotting factors, hormones and immunoglobulin which are used for their therapeutic values.

 

With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry’s growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.

 

The blood plasma market is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, “Global Blood Plasma Market” presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth.

 

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have projected the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables, and tests.

 

1. Overview

 

1.1 Components of Blood Plasma

1.2 Functions of Blood Plasma

1.3 Collection and Extraction of Plasma

 

1.3.1 Plasma Collection
1.3.2 Plasma Extraction
1.3.3 Plasma Fractionation Yield
1.3.4 Plasma Usage

 

2. Blood Plasma Market Analysis

 

2.1 Global Plasma Market
-Market Value
-Market Segmentation
-Breakdown by Region

 

2.1.1 Plasma Industry Cost Structure

 

2.2 Global Immunoglobulin (Ig) Market
-Market Value
-Market Volume
-Demand & Supply
-Volume by Region
-Per Capita Usage

 

2.3 Global Hemophilia Market
-Total Market Value
-Hemophilia A Market
-FVIII Demand & Usage
-Hemophilia B Market
- FIX Consumption
- Hemophilia with Inhibitor Market
- Von Willebrand Disease Market

 

2.4 Global Albumin Market

 

2.4.1 Albumin Market of China and the US

 

3. Market Dynamics

 

3.1 Key Trends

 

3.1.1 Kinetics of Plasma-collection Industry
3.1.2 Growth in the US Immunoglobulin Reimbursement
3.1.3 Rise in the US Plasma Collection Centers
3.1.4 Rising Penetration of Episodic Treatment in Emerging Markets
3.1.5 Rising Share of Developing World in Global FVIII Demand
3.1.6 A1PI (Alpha-1 Proteinase Inhibitor) Deficiency- Confined to Prevention only

 

3.2 Industry Developments

 

3.2.1 Improved Biological Molecule Formulations
3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
3.2.3 Global Fractionation Capacity on the Rise

 

3.3 Growth Drivers

 

3.3.1 Increasing New Patient Registration for Hemophilia Treatment
3.3.2 Increased Penetration of Plasma Derived Products
3.3.3 Rising Healthcare Expenditure
3.3.4 Launch of NMEs (New Molecular Entities)
3.3.5 Growing Ageing Population
3.3.6 Ameliorating Economic Conditions
3.3.7 China Factor

 

3.4 Challenges

 

3.4.1 Increasing Regulation in Plasma-collection Industry
3.4.2 Escalating Price Pressure
3.4.3 Supply Likely to Exceed Demand
3.4.4 Misdiagnosis of the Disease

 

4. Competitive Landscape

 

4.1 Blood Plasma Market Contention
-Market Share
-Sales Comparison

 

4.2 Plasma Derivatives Market Contention

 

4.2.1 Immunoglobulin
-Market Share
-Sales Comparison

 

4.2.2 Hemophilia
- FVIII Market Share
-Recombinant FVIII Market Share


4.2.3 Albumin

 

5. Company Profiles

 

5.1 Baxter International Inc.

 

5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Investment in R&D
-Growth through Acquisitions/Collaborations


5.2 Grifols

 

5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Expansion in Other Geographic Regions
-Growth through Acquisitions in Research Companies

 

5.3 CSL Limited

 

5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on R&D
-Expanding Product Portfolio


5.4 Octapharma AG

 

5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
-Focus on Innovation and Expansion in Markets
-Expansion of R&D and Production Facilities

 

6. Market Outlook

 

6.1 Market Forecast

6.2 Forecast Methodology

 

6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

List of Charts

 

Plasma Extraction from Donated Blood (Recovered Plasma)
Plasmapheresis (Source Plasma)
Global Blood Plasma Market (2000-2013)
Global Plasma Market by Products (ex. Recombinant Factors) (2012)
Global Plasma Market by Region (ex. Recombinant Factors) (2012)
Global Plasma Market by Population (ex. Recombinant Factors) (2012)
Manufacturing Cost Split for Plasma Fractionation (2013)
Global Immunoglobulin Market Size by Value (2004-2013)
Global Immunoglobulin Market Size by Volume (2004-2013)
Immunoglobulin Usage Per Capita in Select Countries (2012)
IVIG Usage Per Capita in Select Countries (2012)
Global IVIG Demand and Supply (2007-2012)
IVIG Market Volume by Region (2008, 2010 and 2012)
IVIG Use by Indication (2013)
Global Hemophilia Treatment Market Revenues (2006-2013E)
Global Hemophilia Treatment Market Outlook (2011-2016F)
Global Hemophilia A Treatment Market Outlook (2011-2016F)
Global Demand for Factor VIII (2010-2016E)
Factor VIII Usage in Select Countries (2012)
Global Hemophilia B Treatment Market Outlook (2011-2016F)
Global FIX Consumption (2005-2013E)
Global Inhibitor Treatment Market Outlook (2011-2016F)
Global Von Willebrand Treatment Market Outlook (2011-2016F)
Albumin Usage in Select Regions and Countries (2012)
Albumin Market Size of the US and China (2012)
Albumin Price across US and China
US Collection Centers (2009-2013)
US Collection Centers by Major Fractionator (2009-2013)
Hemophilia Patients Receiving Episodic Treatment (2010-2017E)*
Hemophilia Patients Receiving Prophylactic Treatment (2012, 2017E)
Demand Patterns for Factor VIII (2012, 2015E and 2020E)
A1PI Statistics of North America and EU
Per Capita FIX Usage in Developed Economies
Per Capita FIX Usage in Emerging Economies (2012)
Global Healthcare Spending (2005-2015E)
Global Ageing Population (2007-2013)
Global Male Population (2005-2014F)
Global GDP (2001-2013)
World GDP per Capita (2005-2012)
Excess Supply in FVIII Market (2010-2016E)
Global Plasma Market Share by Company (2013)
Movements in Global Plasma Market Share (2008-2013)
Global Immunoglobulin Market Share by Company (2013)
Movements in Global Immunoglobulin Market Share (2008-2013)
Global IVIG Market Share (2012)
Factor VIII Market Share by Company (2013)
Recombinant FVIII Market Share by Company (2013)
China’s Albumin Market (2011-12)
Baxter - Sales by Business Segments (2013)
Baxter - Sales by Region (2013)
Revenue and Net Income, Baxter Inc. (2010-2013)
Grifols Revenue Share by Business Segments (2013)
Revenue and Net Income, Grifols (2010-2013)
CSL’s Revenue Share by Major Products (2012-13)
CSL’s Group Sales by Region (2012-13)
Revenue and Net Profit, CSL Ltd. (2009/10-2012/13)
Net Sales and Net Profit, Octapharma AG (2010-2013)
Research and Development Expenditure, Octapharma AG (2010-2013)
Global Blood Plasma Market Forecast (2007-2017F)

 

List of Tables

 

Constituents of Blood Plasma
Recovered plasma vs. Source plasma
Output per Liter of Plasma
US Medicare IG Reimbursement Rates
A1PI Products
Long Acting FIX & FVIII under Late-Stage Development
Extended Half Life rFVIII Agents
Extended Half Life rFIX Agents
Global Fractionation Capacity and Throughput, 2014E
New Patient Registrations in the Worldwide Bleeding Disorders Market (2008-2013E)
Global Availability of NMEs (2012)
rFVIII Product Pipeline
Global Plasma Product Sales by Company (2010-2013)
Global Ig Sales by Company (2010-2013)
Dependent & Independent Variables (2007-2013)
Correlation Matrix
Model Summary - Coefficient of Determination
Regression Coefficients Output

1. Overview
Pages : 10
USD 200

1.1 Components of Blood Plasma

1.2 Functions of Blood Plasma

1.3 Collection and Extraction of Plasma

 

1.3.1 Plasma Collection
1.3.2 Plasma Extraction
1.3.3 Plasma Fractionation Yield
1.3.4 Plasma Usage


Figure 1.1: Plasma Extraction from Donated Blood (Recovered Plasma)
Figure 1.2: Plasmapheresis (Source Plasma)

 

Table 1.1: Constituents of Blood Plasma
Table 1.2: Recovered plasma vs. Source plasma
Table 1.3: Output per Liter of Plasma

 
2. Blood Plasma Market Analysis
Pages : 17
USD 300

2.1 Global Plasma Market
-Market Value
-Market Segmentation
-Breakdown by Region

 

2.1.1 Plasma Industry Cost Structure

 

2.2 Global Immunoglobulin (Ig) Market
-Market Value
-Market Volume
-Demand & Supply
-Volume by Region
-Per Capita Usage

 

2.3 Global Hemophilia Market
-Total Market Value
-Hemophilia A Market
-FVIII Demand & Usage
-Hemophilia B Market
- FIX Consumption
- Hemophilia with Inhibitor Market
- Von Willebrand Disease Market

 

2.4 Global Albumin Market

 

2.4.1 Albumin Market of China and the US

 

Figure 2.1: Global Blood Plasma Market (2000-2013)
Figure 2.2: Global Plasma Market by Products (ex. Recombinant Factors) (2012)
Figure 2.3: Global Plasma Market by Region (ex. Recombinant Factors) (2012)
Figure 2.4: Global Plasma Market by Population (ex. Recombinant Factors) (2012)
Figure 2.5: Manufacturing Cost Split for Plasma Fractionation (2013)
Figure 2.6: Global Immunoglobulin Market Size by Value (2004-2013)
Figure 2.7: Global Immunoglobulin Market Size by Volume (2004-2013)
Figure 2.8: Immunoglobulin Usage Per Capita in Select Countries (2012)
Figure 2.9: IVIG Usage Per Capita in Select Countries (2012)
Figure 2.10: Global IVIG Demand and Supply (2007-2012)
Figure 2.11: IVIG Market Volume by Region (2008, 2010 and 2012)
Figure 2.12: IVIG Use by Indication (2013)
Figure 2.13: Global Hemophilia Treatment Market Revenues (2006-2013E)
Figure 2.14: Global Hemophilia Treatment Market Outlook (2011-2016F)
Figure 2.15: Global Hemophilia A Treatment Market Outlook (2011-2016F)
Figure 2.16: Global Demand for Factor VIII (2010-2016E)
Figure 2.17: Factor VIII Usage in Select Countries (2012)
Figure 2.18: Global Hemophilia B Treatment Market Outlook (2011-2016F)
Figure 2.19: Global FIX Consumption (2005-2013E)
Figure 2.20: Global Inhibitor Treatment Market Outlook (2011-2016F)
Figure 2.21: Global Von Willebrand Treatment Market Outlook (2011-2016F)
Figure 2.22: Albumin Usage in Select Regions and Countries (2012)
Figure 2.23: Albumin Market Size of the US and China (2012)
Figure 2.24: Albumin Price across US and China

 
3. Market Dynamics
Pages : 22
USD 350

3.1 Key Trends

 

3.1.1 Kinetics of Plasma-collection Industry
3.1.2 Growth in the US Immunoglobulin Reimbursement
3.1.3 Rise in the US Plasma Collection Centers
3.1.4 Rising Penetration of Episodic Treatment in Emerging Markets
3.1.5 Rising Share of Developing World in Global FVIII Demand
3.1.6 A1PI (Alpha-1 Proteinase Inhibitor) Deficiency- Confined to Prevention only

 

3.2 Industry Developments

 

3.2.1 Improved Biological Molecule Formulations
3.2.2 Baxter’s Phase I Clinical Trial of Treatment for Hemophilia A
3.2.3 Global Fractionation Capacity on the Rise

 

3.3 Growth Drivers

 

3.3.1 Increasing New Patient Registration for Hemophilia Treatment
3.3.2 Increased Penetration of Plasma Derived Products
3.3.3 Rising Healthcare Expenditure
3.3.4 Launch of NMEs (New Molecular Entities)
3.3.5 Growing Ageing Population
3.3.6 Rising Male Population
3.3.7Ameliorating Economic Conditions
3.3.8 China Factor

 

3.4 Challenges

 

3.4.1 Increasing Regulation in Plasma-collection Industry
3.4.2 Escalating Price Pressure
3.4.3 Supply Likely to Exceed Demand
3.4.4 Misdiagnosis of the Disease

 

Figure 3.1: US Collection Centers (2009-2013)
Figure 3.2: US Collection Centers by Major Fractionator (2009-2013)
Figure 3.3: Hemophilia Patients Receiving Episodic Treatment (2010-2017E)*
Figure 3.4: Hemophilia Patients Receiving Prophylactic Treatment (2012, 2017E)
Figure 3.5: Demand Patterns for Factor VIII (2012, 2015E and 2020E)
Figure 3.6: A1PI Statistics of North America and EU
Figure 3.7: Per Capita FIX Usage in Developed Economies
Figure 3.8: Per Capita FIX Usage in Emerging Economies (2012)
Figure 3.9: Global Healthcare Spending (2005-2015E)
Figure 3.10: Global Ageing Population (2007-2013)
Figure 3.11: Global Male Population (2005-2014F)
Figure 3.12: Global GDP (2001-2013)
Figure 3.13: World GDP per Capita (2005-2012)
Figure 3.14: Excess Supply in FVIII Market (2010-2016E)

 

Table 3.1: US Medicare IG Reimbursement Rates
Table 3.2: A1PI Products
Table 3.3: Long Acting FIX & FVIII under Late-Stage Development
Table 3.4: Extended Half Life rFVIII Agents
Table 3.5: Extended Half Life rFIX Agents
Table 3.6: Global Fractionation Capacity and Throughput, 2014E
Table 3.7 New Patient Registrations in the Worldwide Bleeding Disorders Market (2008-2013E)
Table 3.8: Global Availability of NMEs (2012)
Table 3.9: rFVIII Product Pipeline

 
4. Competitive Landscape
Pages : 8
USD 200

4.1 Blood Plasma Market Contention
-Market Share
-Sales Comparison

 

4.2 Plasma Derivatives Market Contention

 

4.2.1 Immunoglobulin
-Market Share
-Sales Comparison

 

4.2.2 Hemophilia
- FVIII Market Share
-Recombinant FVIII Market Share


4.2.3 Albumin

 

Figure 4.1: Global Plasma Market Share by Company (2013)
Figure 4.2: Movements in Global Plasma Market Share (2008-2013)
Figure 4.3: Global Immunoglobulin Market Share by Company (2013)
Figure 4.4: Movements in Global Immunoglobulin Market Share (2008-2013)
Figure 4.5: Global IVIG Market Share (2012)
Figure 4.6: Factor VIII Market Share by Company (2013)
Figure 4.7: Recombinant FVIII Market Share by Company (2013)
Figure 4.8: China’s Albumin Market (2011-12)

 

Table 4.1: Global Plasma Product Sales by Company (2010-2013)
Table 4.2: Global Ig Sales by Company (2010-2013)

 
5. Company Profiles
Pages : 13
USD 200

5.1 Baxter International Inc.

 

5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Focus on Investment in R&D
-Growth through Acquisitions/Collaborations


5.2 Grifols

 

5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Expansion in Other Geographic Regions
-Growth through Acquisitions in Research Companies

 

5.3 CSL Limited

 

5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
-Focus on R&D
-Expanding Product Portfolio


5.4 Octapharma AG

 

5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
-Focus on Innovation and Expansion in Markets
-Expansion of R&D and Production Facilities

 

Figure 5.1: Baxter - Sales by Business Segments (2013)
Figure 5.2: Baxter - Sales by Region (2013)
Figure 5.3: Revenue and Net Income, Baxter Inc. (2010-2013)
Figure 5.4: Grifols Revenue Share by Business Segments (2013)
Figure 5.5: Revenue and Net Income, Grifols (2010-2013)
Figure 5.6: CSL’s Revenue Share by Major Products (2012-13)
Figure 5.7: CSL’s Group Sales by Region (2012-13)
Figure 5.8: Revenue and Net Profit, CSL Ltd. (2009/10-2012/13)
Figure 5.9: Net Sales and Net Profit, Octapharma AG (2010-2013)
Figure 5.10: Research and Development Expenditure, Octapharma AG (2010-2013)

 
6. Market Outlook
Pages : 6
USD 150

6.1 Market Forecast

6.2 Forecast Methodology

 

6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

 

Figure 6.1: Global Blood Plasma Market Forecast (2007-2017F)


Table 6.1: Dependent & Independent Variables (2007-2013)
Table 6.2: Correlation Matrix
Table 6.3: Model Summary - Coefficient of Determination
Table 6.4: Regression Coefficients Output

 
 
 
About Us    |    PRESS RELEASES    |    RESEARCH REPORTS    |    Contact Us    |    PRIVACY POLICY    |    REFUND POLICY
@ Copyright 2014 Koncept Analytics Pvt Ltd. All Rights Reserved. Web Developed By Vision IT Consultants Pvt Ltd.